Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | RHEB | Q15382 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632479 | 0.78 | CYP2A6 (0.45) | ARCYP2A6MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL16632556 | 0.78 | TTR (0.46) | CYP2A6RHEBMAPTMEN1KMT2A | |
| SCHEMBL16632723 | 0.77 | SLC6A4 (0.49) | ARALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3484014 | 0.75 | KCNA3 (0.40) | ARRHEBALDH1A1MAPTKDM4E | |
| SCHEMBL16632984 | 0.75 | CYP2A6 (0.45) | ARCYP2A6ALDH1A1MAPTKDM4E | |
| SCHEMBL16632742 | 0.73 | CYP2A6 (0.38) | ARCYP2A6MAPTKDM4ESLC6A3 | |
| SCHEMBL3484180 | 0.73 | BRD4 (0.39) | RHEBALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3355529 | 0.73 | AR (0.49) | ARALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL16632454 | 0.72 | AR (0.41) | ARCYP2A6MEN1KMT2ANPC1 | |
| SCHEMBL5584528 | 0.72 | CYP2A6 (0.50) | CYP2A6ALDH1A1MAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | AR 538/4885CYP2A6 2131/4885RHEB 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.